Published in PLoS Pathog on July 29, 2010
Oseltamivir-resistant variants of the 2009 pandemic H1N1 influenza A virus are not attenuated in the guinea pig and ferret transmission models. J Virol (2010) 1.72
Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza viruses. PLoS Pathog (2014) 1.49
Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. Influenza Other Respir Viruses (2013) 1.37
A computational-experimental approach identifies mutations that enhance surface expression of an oseltamivir-resistant influenza neuraminidase. PLoS One (2011) 1.16
Role of permissive neuraminidase mutations in influenza A/Brisbane/59/2007-like (H1N1) viruses. PLoS Pathog (2011) 1.14
Visualizing real-time influenza virus infection, transmission and protection in ferrets. Nat Commun (2015) 1.12
Multidrug resistant 2009 A/H1N1 influenza clinical isolate with a neuraminidase I223R mutation retains its virulence and transmissibility in ferrets. PLoS Pathog (2011) 1.09
Comparative pathology in ferrets infected with H1N1 influenza A viruses isolated from different hosts. J Virol (2011) 1.05
Prolonged influenza virus shedding and emergence of antiviral resistance in immunocompromised patients and ferrets. PLoS Pathog (2013) 1.04
Pandemic H1N1 2009 influenza virus with the H275Y oseltamivir resistance neuraminidase mutation shows a small compromise in enzyme activity and viral fitness. J Antimicrob Chemother (2010) 1.03
Enhanced mammalian transmissibility of seasonal influenza A/H1N1 viruses encoding an oseltamivir-resistant neuraminidase. J Virol (2012) 1.00
Impact of potential permissive neuraminidase mutations on viral fitness of the H275Y oseltamivir-resistant influenza A(H1N1)pdm09 virus in vitro, in mice and in ferrets. J Virol (2013) 0.99
Efficient transmission of pandemic H1N1 influenza viruses with high-level oseltamivir resistance. J Virol (2012) 0.98
Animal models for influenza virus pathogenesis, transmission, and immunology. J Immunol Methods (2014) 0.98
Multiple influenza A (H3N2) mutations conferring resistance to neuraminidase inhibitors in a bone marrow transplant recipient. Antimicrob Agents Chemother (2014) 0.97
Environmental levels of the antiviral oseltamivir induce development of resistance mutation H274Y in influenza A/H1N1 virus in mallards. PLoS One (2011) 0.96
New treatments for influenza. BMC Med (2012) 0.95
Transmission of a 2009 H1N1 pandemic influenza virus occurs before fever is detected, in the ferret model. PLoS One (2012) 0.94
Comparable fitness and transmissibility between oseltamivir-resistant pandemic 2009 and seasonal H1N1 influenza viruses with the H275Y neuraminidase mutation. J Virol (2012) 0.94
Epistatic interactions between neuraminidase mutations facilitated the emergence of the oseltamivir-resistant H1N1 influenza viruses. Nat Commun (2014) 0.91
First Fatal Oseltamivir-Resistant 2009 Pandemic Influenza A (H1N1) Case in an Adult in Korea. Chonnam Med J (2011) 0.91
Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir. Transpl Infect Dis (2010) 0.91
Comparison of the protection of ferrets against pandemic 2009 influenza A virus (H1N1) by 244 DI influenza virus and oseltamivir. Antiviral Res (2012) 0.91
The global spread of drug-resistant influenza. J R Soc Interface (2011) 0.90
Consequences of resistance: in vitro fitness, in vivo infectivity, and transmissibility of oseltamivir-resistant influenza A viruses. Influenza Other Respir Viruses (2013) 0.88
Fitness of neuraminidase inhibitor-resistant influenza A viruses. Curr Opin Virol (2011) 0.87
Genetic diversity among pandemic 2009 influenza viruses isolated from a transmission chain. Virol J (2013) 0.87
Novel genotyping and quantitative analysis of neuraminidase inhibitor resistance-associated mutations in influenza a viruses by single-nucleotide polymorphism analysis. Antimicrob Agents Chemother (2011) 0.86
Cloned defective interfering influenza virus protects ferrets from pandemic 2009 influenza A virus and allows protective immunity to be established. PLoS One (2012) 0.86
Changes to the dynamic nature of hemagglutinin and the emergence of the 2009 pandemic H1N1 influenza virus. Sci Rep (2015) 0.85
Nosocomial outbreak of the pandemic Influenza A (H1N1) 2009 in critical hematologic patients during seasonal influenza 2010-2011: detection of oseltamivir resistant variant viruses. BMC Infect Dis (2013) 0.85
A mathematical framework for estimating pathogen transmission fitness and inoculum size using data from a competitive mixtures animal model. PLoS Comput Biol (2011) 0.84
Comparison of ribavirin and oseltamivir in reducing mortality and lung injury in mice infected with mouse adapted A/California/04/2009 (H1N1). Life Sci (2012) 0.84
Prokaryote-expressed M2e protein improves H9N2 influenza vaccine efficacy and protection against lethal influenza A virus in mice. Virol J (2013) 0.83
Severity of clinical disease and pathology in ferrets experimentally infected with influenza viruses is influenced by inoculum volume. J Virol (2014) 0.83
Competitive fitness of influenza B viruses with neuraminidase inhibitor-resistant substitutions in a coinfection model of the human airway epithelium. J Virol (2015) 0.81
Antibiotic resistance as collateral damage: the tragedy of the commons in a two-disease setting. Math Biosci (2015) 0.77
Synthesis of novel N-acetylneuraminic acid derivatives as substrates for rapid detection of influenza virus neuraminidase. Carbohydr Res (2012) 0.77
Q&A: H1N1 pandemic influenza--what's new? BMC Biol (2010) 0.77
Increased virulence of neuraminidase inhibitor-resistant pandemic H1N1 virus in mice: potential emergence of drug-resistant and virulent variants. Virulence (2013) 0.77
Intranasal administration of poly-gamma glutamate induced antiviral activity and protective immune responses against H1N1 influenza A virus infection. Virol J (2015) 0.77
Pandemic Seasonal H1N1 Reassortants Recovered from Patient Material Display a Phenotype Similar to That of the Seasonal Parent. J Virol (2016) 0.75
Competitive Fitness of Influenza B Viruses Possessing E119A and H274Y Neuraminidase Inhibitor Resistance-Associated Substitutions in Ferrets. PLoS One (2016) 0.75
The Nature of Exposure Drives Transmission of Nipah Viruses from Malaysia and Bangladesh in Ferrets. PLoS Negl Trop Dis (2016) 0.75
Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med (2009) 42.75
Universal primer set for the full-length amplification of all influenza A viruses. Arch Virol (2001) 21.17
Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet (2004) 8.62
Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA (2006) 8.06
Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate. Anal Biochem (1979) 7.09
Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA (2009) 5.84
Review of aerosol transmission of influenza A virus. Emerg Infect Dis (2006) 5.31
Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis (2007) 5.21
Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J Virol (2003) 5.11
The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res (2002) 4.85
Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis (2004) 4.82
Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb Mortal Wkly Rep (2009) 4.36
Global transmission of oseltamivir-resistant influenza. N Engl J Med (2009) 4.34
Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother (2003) 3.90
Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg Infect Dis (2009) 3.76
Aerosol transmission of influenza A virus: a review of new studies. J R Soc Interface (2009) 3.61
Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother (2005) 3.53
Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009. MMWR Morb Mortal Wkly Rep (2009) 3.43
Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res (2009) 3.39
Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clin Infect Dis (2009) 3.37
Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J Infect Dis (2006) 3.28
Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis--North Carolina, 2009. MMWR Morb Mortal Wkly Rep (2009) 3.27
Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res (2002) 3.07
Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob Agents Chemother (2005) 3.04
Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Res (2002) 3.04
Immunity to respiratory viruses. Annu Rev Immunol (2009) 2.50
Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir. PLoS Pathog (2008) 2.49
A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. N Engl J Med (2009) 2.36
Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. N Engl J Med (2009) 2.24
Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir Ther (2006) 2.22
Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob Agents Chemother (2007) 2.03
Oseltamivir-resistant influenza A viruses are transmitted efficiently among guinea pigs by direct contact but not by aerosol. J Virol (2008) 1.95
Influenza A (H1N1) virus, 2009--online monitoring. N Engl J Med (2009) 1.62
Understanding influenza transmission, immunity and pandemic threats. Influenza Other Respir Viruses (2009) 1.60
RNA virus fitness. Rev Med Virol (1997) 1.55
The evolution of influenza resistance and treatment. JAMA (2009) 1.40
Detection of an oseltamivir-resistant pandemic influenza A/H1N1 virus in Hong Kong. J Clin Virol (2009) 1.39
First cases of spread of oseltamivir resistant swine flu between patients are reported in Wales. BMJ (2009) 0.93
Quantitative SNP-detection method for estimating HIV-1 replicative fitness: application to protease inhibitor-resistant viruses. Microbiol Immunol (2006) 0.80
Current challenges in the risk assessment of neuraminidase inhibitor-resistant influenza viruses. J Infect Dis (2010) 0.80
Community-acquired oseltamivir-resistant pandemic (H1N1) 2009 in child, Israel. Emerg Infect Dis (2010) 0.79
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
Large-scale sequence analysis of avian influenza isolates. Science (2006) 9.87
Lethal H5N1 influenza viruses escape host anti-viral cytokine responses. Nat Med (2002) 9.47
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature (2012) 8.13
Molecular basis of replication of duck H5N1 influenza viruses in a mammalian mouse model. J Virol (2005) 7.36
Are we ready for pandemic influenza? Science (2003) 7.20
The polymerase complex genes contribute to the high virulence of the human H5N1 influenza virus isolate A/Vietnam/1203/04. J Exp Med (2006) 5.94
Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004. J Virol (2005) 5.40
Reemerging H5N1 influenza viruses in Hong Kong in 2002 are highly pathogenic to ducks. J Virol (2004) 5.17
Investigation of outbreaks of highly pathogenic H5N1 avian influenza in waterfowl and wild birds in Hong Kong in late 2002. Avian Pathol (2004) 5.08
Human infection with an avian H9N2 influenza A virus in Hong Kong in 2003. J Clin Microbiol (2005) 5.04
Influenza A viruses of migrating wild aquatic birds in North America. Vector Borne Zoonotic Dis (2004) 4.89
The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. Immunity (2009) 4.51
H5N1 influenza--continuing evolution and spread. N Engl J Med (2006) 4.47
Eight-plasmid system for rapid generation of influenza virus vaccines. Vaccine (2002) 4.45
Dating the emergence of pandemic influenza viruses. Proc Natl Acad Sci U S A (2009) 4.36
Dynamic T cell migration program provides resident memory within intestinal epithelium. J Exp Med (2010) 4.09
Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother (2006) 4.02
Inefficient transmission of H5N1 influenza viruses in a ferret contact model. J Virol (2007) 3.79
TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. Proc Natl Acad Sci U S A (2009) 3.70
Gain-of-function experiments on H7N9. Science (2013) 3.67
MERS coronaviruses in dromedary camels, Egypt. Emerg Infect Dis (2014) 3.64
The genesis and source of the H7N9 influenza viruses causing human infections in China. Nature (2013) 3.60
Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med (2007) 3.57
Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J Infect Dis (2006) 3.28
The influenza virus gene pool in a poultry market in South central china. Virology (2003) 3.25
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol (2012) 3.08
Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob Agents Chemother (2005) 3.04
Domestic ducks and H5N1 influenza epidemic, Thailand. Emerg Infect Dis (2006) 2.98
Characterization of H5N1 influenza viruses that continue to circulate in geese in southeastern China. J Virol (2002) 2.97
Influenza in migratory birds and evidence of limited intercontinental virus exchange. PLoS Pathog (2007) 2.94
Mutations in the NS1 protein of swine influenza virus impair anti-interferon activity and confer attenuation in pigs. J Virol (2005) 2.88
Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo. J Virol (2007) 2.77
Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J Infect Dis (2006) 2.76
Identification of H2N3 influenza A viruses from swine in the United States. Proc Natl Acad Sci U S A (2007) 2.73
Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J Infect Dis (2005) 2.72
Inhibition of the cytokine response does not protect against lethal H5N1 influenza infection. Proc Natl Acad Sci U S A (2007) 2.63
Structure of antigenic sites on the haemagglutinin molecule of H5 avian influenza virus and phenotypic variation of escape mutants. J Gen Virol (2002) 2.63
Nrf2, a multi-organ protector? FASEB J (2005) 2.61
Studies of H5N1 influenza virus infection of pigs by using viruses isolated in Vietnam and Thailand in 2004. J Virol (2005) 2.56
Pathogenic and antigenic properties of phylogenetically distinct reassortant H3N2 swine influenza viruses cocirculating in the United States. J Clin Microbiol (2003) 2.55
H3N2 influenza virus transmission from swine to turkeys, United States. Emerg Infect Dis (2004) 2.53
The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease. Antioxid Redox Signal (2009) 2.49
The influenza virus enigma. Cell (2009) 2.48
Persistent host markers in pandemic and H5N1 influenza viruses. J Virol (2007) 2.42
Multiple reassortment between pandemic (H1N1) 2009 and endemic influenza viruses in pigs, United States. Emerg Infect Dis (2011) 2.42
Long-term evolution and transmission dynamics of swine influenza A virus. Nature (2011) 2.39
Epitope mapping of the hemagglutinin molecule of a highly pathogenic H5N1 influenza virus by using monoclonal antibodies. J Virol (2007) 2.39
Comparative sequence analysis of the symbiosis island of Mesorhizobium loti strain R7A. J Bacteriol (2002) 2.37
Avian flu: Gain-of-function experiments on H7N9. Nature (2013) 2.32
Influenza: emergence and control. J Virol (2004) 2.31
Pause on avian flu transmission research. Science (2012) 2.24
Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. Antiviral Res (2002) 2.22
Adaptation of pandemic H1N1 influenza viruses in mice. J Virol (2010) 2.22
Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respir Res (2006) 2.15
Pathogenesis of Hong Kong H5N1 influenza virus NS gene reassortants in mice: the role of cytokines and B- and T-cell responses. J Gen Virol (2005) 2.15
Retracted The NS1 gene of H5N1 influenza viruses circumvents the host anti-viral cytokine responses. Virus Res (2004) 2.15
Protection and compensation in the influenza virus-specific CD8+ T cell response. Proc Natl Acad Sci U S A (2003) 2.13
Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines. Proc Natl Acad Sci U S A (2005) 2.13
Changes in H5N1 influenza virus hemagglutinin receptor binding domain affect systemic spread. Proc Natl Acad Sci U S A (2008) 2.11
Diversity of influenza viruses in swine and the emergence of a novel human pandemic influenza A (H1N1). Influenza Other Respir Viruses (2009) 2.11
Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res (2006) 2.11
Ducks: the "Trojan horses" of H5N1 influenza. Influenza Other Respir Viruses (2009) 2.10
Host genetic variation affects resistance to infection with a highly pathogenic H5N1 influenza A virus in mice. J Virol (2009) 2.08
Role of quail in the interspecies transmission of H9 influenza A viruses: molecular changes on HA that correspond to adaptation from ducks to chickens. J Virol (2003) 2.07
Hemagglutinin-neuraminidase balance confers respiratory-droplet transmissibility of the pandemic H1N1 influenza virus in ferrets. Proc Natl Acad Sci U S A (2011) 2.04